N03AX15 · Nervous system
Zonisamide Viatris (previously Zonisamide Mylan)
Indications
Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above.
Composition
- Active substance
- zonisamide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Zonisamide Viatris (previously Zonisamide Mylan)
- Active substance
- zonisamide
- ATC code
- N03AX15
- Group
- Nervous system
- Therapeutic area
- Epilepsy
- Marketing authorisation holder
- Viatris Limited